News
AQST
4.105
-8.78%
-0.395
Coming FDA Approvals Could Send These 3 Drug Stocks Soaring
FDA approval is the number one needle mover for drug stocks. FDA approval for a drug or treatment can bring years of steady, high-margin revenue to a company. Three companies are awaiting key FDA decisions over the next couple of months. Merck & Co, Amgen and Aquestive Therapeutics are among the companies awaiting key decisions.
Investorplace · 2d ago
Weekly Report: what happened at AQST last week (0408-0412)?
Weekly Report · 4d ago
Aquestive Therapeutics a new overweight at Piper on oral film products
Aquestive Therapeutics a new overweight at Piper on oral film products. The firm has a $10 price target for the stock. Piper Sandler says the company is poised for value creation through its proprietary oral film, PharmFilm, to deliver existing medicines. Piper's David Absellem likes Anaphylm, an oral film of epinephrine to treat anaphylaxis.
Seeking Alpha · 04/11 18:48
Piper starts Aquestive at overweight, cites allergy reaction treatment
Healthcare Piper starts Aquestive at overweight, cites allergy reaction treatment Anaphylm. Piper Sandler started coverage of aquestive Therapeutics with an overweight rating. The investment firm cites the market potential for its allergic reaction treatment. Piper believes data for Anaphylm supports potential FDA approval in 2025.
Seeking Alpha · 04/11 16:38
Aquestive Therapeutics Initiated at Overweight by Piper Sandler
Dow Jones · 04/11 10:04
Aquestive Therapeutics Price Target Announced at $10.00/Share by Piper Sandler
Dow Jones · 04/11 10:04
Piper Sandler Initiates Coverage On Aquestive Therapeutics with Overweight Rating, Announces Price Target of $10
Benzinga · 04/11 09:54
AQUESTIVE THERAPEUTICS INC <AQST.O>: PIPER SANDLER INITIATES COVERAGE WITH OVERWEIGHT RATING; TARGET PRICE $10
Reuters · 04/11 04:38
Aquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024
Aquestive Therapeutics has achieved positive Phase III data for their Anaphylm epinephrine sublingual film, showing comparable efficacy to auto-injectors. The company is moving forward with plans to file a New Drug Application (NDA) in 2024. Aquestive has the potential to disrupt the market dominated by auto- injectors with global peak sales projected to surpass $1 billion.
Seeking Alpha · 04/09 05:25
Weekly Report: what happened at AQST last week (0401-0405)?
Weekly Report · 04/08 11:29
Analysts Offer Insights on Healthcare Companies: eFFECTOR Therapeutics (EFTR), Adagene (ADAG) and Aquestive Therapeutics (AQST)
TipRanks · 04/05 10:30
Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
STAAR Surgical shares jumped 13.3% to $44.30 on Thursday. The company issued strong preliminary first-quarter net sales guidance. TC Biopharm (Holdings) Plc shares climbed 130.1% in the mid-day session.
Benzinga · 04/04 17:21
Lamb Weston Reports Weak Earnings, Joins Paragon 28, Resources Connection And Other Big Stocks Moving Lower On Thursday
Shares of Lamb Weston Holdings, Inc. Tumbled 17.5% to $83.40 on Thursday. The company reported weak third-quarter results and cut its FY24 outlook. The Dow Jones gained over 150 points in Thursday's session. Other big U.S. Stocks also recorded losses.
Benzinga · 04/04 14:44
Aquestive Therapeutics files for $250M mixed securities shelf
Healthcare Aquestive Therapeutics files for $250M mixed securities shelf. The company filed a prospectus related to the offer and sale of $250 million mixed securities. Aquestives Therapeutic, Inc. (AQST) stock.
Seeking Alpha · 04/03 21:38
AQUESTIVE THERAPEUTICS FILES FOR MIXED SHELF OFFERING OF UP TO $250 MLN - SEC FILING
Reuters · 04/03 21:29
Aquestive Therapeutics Welcomes Abigail Jenkins to Board
TipRanks · 04/01 12:33
*Aquestive Therapeutics Appoints Abigail Jenkins to the Company's Bd of Directors >AQST
Dow Jones · 04/01 12:05
*Aquestive Therapeutics: Jenkins Is Pres and Chief Executive Officer of Gamida Cell Ltd >AQST
Dow Jones · 04/01 12:05
AQUESTIVE THERAPEUTICS INC - BOARD OF DIRECTORS WILL NOW BE COMPRISED OF EIGHT DIRECTORS
Reuters · 04/01 12:00
AQUESTIVE THERAPEUTICS STRENGTHENS BOARD OF DIRECTORS WITH EXPERIENCED BIOTECH EXECUTIVE
Reuters · 04/01 12:00
More
Webull provides a variety of real-time AQST stock news. You can receive the latest news about Aquestive Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About AQST
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies. It is advancing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis. It has also developed a product pipeline focused on treating diseases of the central nervous system (CNS). Its PharmFilm technology is comprised of proprietary polymer compositions that serve as film formers to hold active pharmaceutical ingredients (APIs), and excipients in place. Its product portfolio and pipeline include Anaphylm, AQST-108, and Adrenaverse. Its CNS product candidate include Libervant. The Company’s Licensed commercial products and product candidates and other product includes Suboxone, Exservan, KYNMOBI, Zuplenz, Azstarys, Libervant, and Sympazan. Anaphylm is a non-device based, orally delivered epinephrine product candidate.